Umberto Cillo, Laura Saracino, Alessandro Vitale, Alessandra Bertacco, Mauro Salizzoni, Francesco Lupo, Michele Colledan, Vittorio Corno, Giorgio Rossi, Paolo Reggiani, Umberto Baccarani, Vittorio Bresàdola, Luciano De Carlis, Iacopo Mangoni, Raphael Ramirez Morales, Salvatore Agnes, Erida Nure – 28 December 2018 – Early everolimus (EVR) introduction and tacrolimus (TAC) minimization after liver transplantation may represent a novel immunosuppressant approach. This phase 2, multicenter, randomized, open‐label trial evaluated the safety and efficacy of early EVR initiation.

Gil Ben‐Yakov, Hawwa Alao, John P. Haydek, Nancy Fryzek, Min Ho Cho, Mehdi Hemmati, Vikram Samala, Margaret Shovlin, Kieron Dunleavy, Wyndham Wilson, Elizabeth C. Jones, Yaron Rotman – 28 December 2018 – Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for de novo steatosis during chemotherapy for non‐Hodgkin lymphoma (NHL).

Julie Di Martino, Patrice Mascalchi, Philippe Legros, Sabrina Lacomme, Etienne Gontier, Paulette Bioulac‐Sage, Charles Balabaud, Violaine Moreau, Frédéric Saltel – 28 December 2018 – Liver sinusoidal endothelial cells (LSECs) possess fenestrae, which are key for the exchange between blood and hepatocytes. Alterations in their number or diameter have important implications for hepatic function in liver diseases. They are lost early in the development of hepatic fibrosis through a process called capillarization.

Barbara Ulmasov, Hidenao Noritake, Peter Carmichael, Kiyoko Oshima, David W. Griggs, Brent A. Neuschwander‐Tetri – 27 December 2018 – The presence and stage of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) is strongly associated with mortality. Thus, both preventing and reversing fibrosis are critically important approaches to prevent death or the need for liver transplantation from NASH.

Matthew T. Quirk, David S. Lu – 27 December 2018

Dianne LaPointe Rudow, Samantha DeLair, Thomas Feeley, Sander Florman, James Guarrera, Milan Kinkhabwala, Mark Orloff, Lewis Teperman, Glyn Morgan – 27 December 2018 – Outcomes for adult‐to‐adult living liver donors (LDs) are largely based on short‐term data drawn from single‐center studies. The aim of this study was to determine how living liver donation (LLD) impacts self‐reported quality‐of‐life (QOL) up to 6 years after donation in a sample of residents from New York State.

Suzanne R. Sharpton, Norah A. Terrault, Andrew M. Posselt – 27 December 2018 – Morbid obesity (body mass index [BMI] ≥40 kg/m2) is a relative contraindication to liver transplantation (LT) at many transplant centers. The safety and efficacy of pre‐LT bariatric surgery in morbidly obese LT candidates is unknown. Herein, we describe a cohort study of morbidly obese LT candidates who failed to achieve adequate weight loss through a medically supervised weight loss program and subsequently underwent sleeve gastrectomy (SG) at our institution.

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.

Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Takahiro Seimiya, Tatsunori Suzuki, Eri Tanaka, Rei Ishibashi, Kazuyoshi Funato, Kazuhiko Koike – 26 December 2018 – Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV‐related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented.

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.